<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245361</url>
  </required_header>
  <id_info>
    <org_study_id>P1200/001</org_study_id>
    <nct_id>NCT01245361</nct_id>
  </id_info>
  <brief_title>A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit</brief_title>
  <acronym>UA-IFX</acronym>
  <official_title>&quot;A Comparative Study Of A 6-Month Infliximab (Remicade®) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis (RA) : Clinical, Radiological (MRI) And Synovial Benefit P1200/001&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patrick Durez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with undifferentiated arthritis and the presence of anti-citruline (anti-CCP)
      antibodies are at high risk to develop RA. The presence of anti-CCP is associated with a
      higher rate of erosion and a higher risk of progressive and severe RA.

      The investigators have demonstrated in the CIERA study that MTX/IFX combination therapy is
      superior to MTX alone to reduce MRI signs of synovitis and bone edema and is clinically more
      effective.

      The immunopathogenesis of undifferentiated arthritis is poorly understood. However, synovial
      studies from patients with early arthritis suggest that UA and RA may share common
      immunopathogenic mechanisms. One biopsy study of asymptomatic joints in patients with early
      arthritis demonstrates synovitis in more than half of the joints samples with prominent T
      cell and macrophage infiltration, similar to Rheumatoid Arthritis (RA).

      Thus intensive treatment with anti-TNF antibodies (infliximab) may have an impact on multiple
      immune mechanisms driving synovitis in undifferentiated arthritis and may influence the
      clinical outcome.

      Recently, Methotrexate has been demonstrated to improve the course of undifferentiated
      arthritis and prevent the development of RA. Short regimen of more intensive therapy with
      Infliximab could alter the radiological, immunopathological and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      not necessary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective To compare the induction therapy with infliximab versus placebo on the MRI synovitis and erosion score in undifferentiated arthritis.</measure>
    <time_frame>2 years</time_frame>
    <description>not necessary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To test the hypothesis that induction therapy with infliximab is followed by a better clinical outcome over a 2 year follow-up and defined as a lower rate of patients with ACR criteria at 6, 12 and 24 months.</measure>
    <time_frame>2 years</time_frame>
    <description>no necessary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of infliximab on synovial histopathology of UA.</measure>
    <time_frame>2 years</time_frame>
    <description>no necessary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test the hypothesis that infliximab can influence the presence of anti CCP antibodies.</measure>
    <time_frame>2 years</time_frame>
    <description>no necessary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess physical function and health-related quality of life using the Disability Index of HAQ (HAQ) and questionnaire &quot;SF-36&quot; instruments, respectively</measure>
    <time_frame>2 years</time_frame>
    <description>no necessary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Undifferentiated Arthritis</condition>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group I: Infliximab 3 mg/kg wk 0,2,6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 3 mg/kg wk 0,2,6</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>FR-BR7794</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride</intervention_name>
    <description>Group II : Placebo wk 0,2,6</description>
    <arm_group_label>sodium chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of UA Absence of American College of Rheumatology (ACR) criteria Active UA
        defined by a swollen joint count ≥ 1 and &lt; 4 Positive anti-CCP Disease duration &lt; 2 years
        DMARDs naive No chronic treatment with steroids (&gt; 3 months), if needed washout of 4 weeks
        NSAIDs stable

        Exclusion Criteria:

        Other rheumatic inflammatory diagnosis Contraindication to MRI (pace-maker, etc.)
        Congestive heart disease Active or latent tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Durez, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université Catholique de Louvain</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2010</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Patrick Durez</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Undifferentiated Arthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

